{"query":"Exagen John Aballi autoimmune diagnostics news","follow_up_questions":null,"answer":null,"images":[],"results":[{"url":"https://investors.exagen.com/news-releases/news-release-details/exagen-inc-completes-validation-and-regulatory-submission-new?mobile=1&mobile=1&mobile=1&mobile=1&mobile=1","title":"Exagen Inc. Completes Validation and Regulatory Submission for ...","content":"CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) biomarkers, to be incorporated into the AVISE CTD platform. Collectively, these new biomarkers will further improve the clinical utility of AVISE CTD, providing clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. “The AVISE CTD enhancements are a direct result of our continuing commitment to develop and deliver testing solutions that address the challenges of clinicians searching for answers for suspected autoimmune patients,” said John Aballi, CEO, Exagen. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation Exagen’s goals, strategies and ambitions; potential future financial and business performance; the potential for Exagen’s research to lead to positive impacts to patients; the potential for Exagen’s research to lead to new or improved testing products; the potential utility and effectiveness of Exagen’s services and testing solutions; the potential value of updates being made to AVISE® CTD; potential shareholder value and growth and 2024 guidance.","score":0.8965509,"raw_content":null},{"url":"https://investors.exagen.com/news-releases/news-release-details/exagen-announces-appointment-john-aballi-ceo?mobile=1&mobile=1&mobile=1&mobile=1&mobile=1","title":"Exagen Announces Appointment of John Aballi as CEO","content":"Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President.","score":0.7445268,"raw_content":null},{"url":"https://investors.exagen.com/news-releases/news-release-details/exagen-inc-achieves-key-milestone-1000000th-patient-tested?mobile=1&mobile=1&mobile=1&mobile=1&mobile=1","title":"Exagen Inc. Achieves Key Milestone with 1000000th Patient Tested ...","content":"Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD | Exagen. Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD. CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000 th AVISE CTD test, marking a significant milestone that underscores the company’s dedication to supporting patients and clinicians managing connective tissue diseases (CTD) and other autoimmune conditions. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation Exagen’s goals, strategies and ambitions; potential future financial and business performance; the potential for Exagen’s research to lead to positive impacts to patients; the potential for Exagen’s research to lead to new or improved testing products; the potential utility and effectiveness of Exagen’s services and testing solutions; the potential value of updates being made to AVISE® CTD; potential shareholder value and growth and 2024 guidance.","score":0.6877354,"raw_content":null},{"url":"https://www.stocktitan.net/news/XGN/page-7.html","title":"XGN - Exagen Inc. Latest Stock News & Market Updates - Stock Titan","content":"Exagen Inc. (Nasdaq: XGN) has appointed John Aballi as its new CEO and President, succeeding Ron Rocca, who led the company for 11 years. Aballi brings","score":0.6599319,"raw_content":null},{"url":"https://www.quiverquant.com/news/Exagen+Inc.+Celebrates+Milestone+of+1%2C000%2C000+AVISE+CTD+Tests+Completed+for+Autoimmune+Diagnostics","title":"Exagen Inc. Celebrates Milestone of 1,000,000 AVISE CTD Tests ...","content":"Exagen Inc. achieves its 1,000,000th AVISE CTD test, enhancing autoimmune disease diagnosis and patient care.","score":0.6307082,"raw_content":null}],"response_time":1.09,"request_id":"8f7e0341-f3bb-4cb5-a560-c2886dfe06f0"}